+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunocompetence and malignant lymphoma: immunologic status before therapy

Immunocompetence and malignant lymphoma: immunologic status before therapy

Cancer 48(12): 2702-2709

One-hundred-eighty-six previously untreated patients with malignant lymphoma were evaluated for immunocompetence by means of several tests of immune function: total circulating lymphocytes, T cells (E-rosettes), B cells (EAC-rosettes), delayed hypersensitivity to six recall antigens, serum immunoglobulins, mixed lymphocyte culture, and lymphocyte mitogenic response to phytohemagglutinin and pokeweed mitogen. The results were correlated with histology, stage, and clinical features. Diffuse lymphomas, especially diffuse histiocytic (large cell) (DHL), were associated with decreased absolute lymphocytes and E-rosette forming cells. Skin test reactivity varied with both histology and stage. For example, only one of six tests was impaired in diffuse lymphocytic well differentiated (DLWD) lymphoma in contrast to two of six in localized DHL and five of six in advanced DHL. Patients with nodular lymphoma exhibited depressed mean levels of IgA and IgG, while only IgA was significantly decreased in diffuse lymphoma. Mitogen stimulation was depressed in all groups, although mixed lymphocyte cultures did not differ significantly from controls. In summary, there is a spectrum of immunodeficiency of both B and T cell type in patients with malignant lymphoma that correlated with histology and stage. Implications and possible mechanisms of these observations are discussed.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 043330348

Download citation: RISBibTeXText

PMID: 6458352

DOI: 10.1002/1097-0142(19811215)48:12<2702::aid-cncr2820481224>3.0.co;2-l

Related references

Immunocompetence Of Patients With Malignant Lymphoma. Nippon Jibiinkoka Gakkai Kaiho 82(7): 682-688, 1979

Monitoring of immunologic status of patients receiving BCG therapy for malignant disease. Cancer 37(5): 2183-2193, 1976

The current status and future applications of gene therapy and immunogene therapy for malignant lymphoma. Nihon Rinsho. Japanese Journal of Clinical Medicine 58(3): 715-719, 2000

The immunologic approach to analysis of malignant lymphoma. Mantle zone lymphoma of the ileocecal region. Journal of Clinical Gastroenterology 9(5): 588-598, 1987

Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 7(3): 398-403, 1993

Pathologic and immunologic characterization of malignant lymphoma in Taiwan. With special reference to retrovirus-associated adult T-cell lymphoma/leukemia. American Journal of Clinical Pathology 84(6): 715-723, 1985

Current status of the problem of malignant lymphoma (on the centenary of the theory of malignant lymphoma). Arkhiv Patologii 46(12): 13-20, 1984

Investigation of the cellular immunocompetence in chronic lymphatic leukemia and malignant lymphoma patients as assessed by the local graft versus host reaction in rats. Journal of the Reticuloendothelial Society 16(5): 276-281, 1974

Immunocompetence of patients with malignant lymphoma (comparative study to that of patients with head and neck cancer). Nihon Jibiinkoka Gakkai Kaiho 82(7): 682-688, 1979

Immunologic phenotype of malignant lymphoma. Nihon Rinsho. Japanese Journal of Clinical Medicine 50(6): 1223-1228, 1992

Malignant lymphoma. Advances in diagnosis and treatment. III. Practice of diagnosis (Standard therapy). 1. Standard therapy of malignant lymphoma (Hodgkin's disease and non-Hodgkin's lymphoma ). Nihon Naika Gakkai Zasshi 90(6): 997-1002, 2001

Immunologic deficiency, autoimmune disease and malignant lymphoma. Nihon Rinsho. Japanese Journal of Clinical Medicine 35(10): 3680-3687, 1977

The so-called immunologic classification of non-Hodgkin's malignant lymphoma. Ceskoslovenska Patologie 11(4): 161-168, 1975

Therapy of high malignant Non-Hodgkin-Lymphoma (NHL) stage I, of low malignant NHL stages I and II, and of centroblastic-centrocytic lymphoma stages IIII. Journal of Cancer Research and Clinical Oncology 111(1 Suppl.): S5-0, 1986

Malignant lymphoma--recent progress in diagnosis and treatment. 3. Progress in therapeutic results. (3). Present status and problems of treatment of malignant lymphoma in Japan. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 72(10): 1336-1341, 1983